secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2026-05-18T20:51:59+00:00
Accession:  0001193125-26-229076
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences WVE-006 phase 1b/2a data shows MZ-like phenotype with monthly dosing, FDA feedback expected mid-2026
--------------------------------------------------------------------------------

- WVE-006 achieved 64.4% wild-type M-AAT (matching protective MZ phenotype) and 70.5% reduction in toxic Z-AAT in 200 mg biweekly cohort.
- Monthly 400 mg dosing yielded similar results: 58.7% M-AAT, 67.7% Z-AAT reduction, and 13.6 µM total AAT.
- Dynamic AAT production restored during acute phase responses (common cold); CRP and AAT strongly correlated (r=0.73, p<0.001).
- WVE-006 well tolerated with no serious AEs or liver toxicities; monthly subcutaneous dosing confirmed feasible.
- Wave expects FDA feedback on accelerated approval pathway mid-2026; 600 mg monthly cohort data due H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312526229076/0001193125-26-229076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312526229076/d154261d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-229076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer